These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35997890)

  • 1. Role of baseline
    Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF
    Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
    Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
    Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative
    Kuo PH; Morris MJ; Hesterman J; Kendi AT; Rahbar K; Wei XX; Fang B; Adra N; Garje R; Michalski JM; Chi K; de Bono J; Fizazi K; Krause B; Sartor O; Tagawa ST; Ghebremariam S; Brackman M; Wong CC; Catafau AM; Benson T; Armstrong AJ; Herrmann K
    Radiology; 2024 Aug; 312(2):e233460. PubMed ID: 39162634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?
    Has Simsek D; Kuyumcu S; Karadogan S; Oflas M; Isik EG; Ozkan ZG; Paksoy N; Ekmekcioglu O; Ekenel M; Sanli Y
    Ann Nucl Med; 2021 Jun; 35(6):680-690. PubMed ID: 33783752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of [
    Pan J; Zhao J; Ni X; Zhu B; Hu X; Wang Q; Wei Y; Zhang T; Gan H; Wang B; Wu J; Song S; Liu C; Ye D; Zhu Y
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1822-1832. PubMed ID: 36719427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mCRPC Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Mdlophane A; Maes A; Mokoala K; Mathabe K; Van C; Wiele D; Morgenstern A
    J Nucl Med; 2022 Oct; 63(10):1496-1502. PubMed ID: 35177427
    [No Abstract]   [Full Text] [Related]  

  • 8. Pre-treatment
    Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
    Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early molecular imaging response assessment based on determination of total viable tumor burden in [
    Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Shagera QA; Artigas C; Karfis I; Critchi G; Chanza NM; Sideris S; Peltier A; Paesmans M; Gil T; Flamen P
    J Nucl Med; 2022 Aug; 63(8):1191-1198. PubMed ID: 34772793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
    Calderoni L; Maietti E; Farolfi A; Mei R; Louie KS; Groaning M; Fanti S
    J Nucl Med; 2023 Jun; 64(6):910-917. PubMed ID: 36635087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
    Michalski K; Mix M; Meyer PT; Ruf J
    Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
    Özülker T; Özülker F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between whole body volumetric parameters of
    Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of volumetric parameters obtained from
    Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
    Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
    Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA
    Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of tumor sink effect: Insights from
    Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
    Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Visually Calculated SUV
    Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L
    J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137
    [No Abstract]   [Full Text] [Related]  

  • 19. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?
    Karyağar S; Güven O; Karyağar SS; Arici S; Selvi O; Geredeli Ç; Özülker F
    Nucl Med Commun; 2021 Sep; 42(9):1011-1016. PubMed ID: 33958536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.